Britain and America have hammered out a significant commercial pact that will preserve no import taxes on UK drug exports going into the US market.
The Terms of the Accord
As part of the deal, the UK has agreed to increase spending on medicines through the National Health Service (NHS). This move guarantees that duties on these crucial products will stay at zero for a duration of three years.
This agreement follows previous threats to dramatically increase import taxes on patented pharmaceutical imports, with figures mentioned up to double the cost.
"This agreement between the Britain strengthens the worldwide climate for cutting-edge drugs and establishes much-needed balance to transatlantic medicine commerce," a release noted.
Economic Importance
Drugs represent one of the the United Kingdom's largest exports to the America, which is by far the primary market for leading British pharmaceutical firms.
Statistics indicate that in the one-year period leading up to September, the UK exported medicines totaling £11.1bn to the US. This amount accounted for nearly one-fifth of total UK exports in that period.
"This guarantee protects employment, increases investment and sets the stage for the UK to establish itself as a worldwide center for life sciences," a minister commented.
Detailed UK Commitments
The pact involves several key changes from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it judges new medicines to be too expensive by a quarter.
- Boosted Medicine Funding: There is a target to double overall public funding on drugs from 0.3 percent of GDP to 0.6% over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must refund to the NHS to prevent overspending will be limited at fifteen percent. Previously, repayments exceeded 20%.
Industry Background
The pact follows a protracted dispute between the drug companies and the British authorities over spending levels and regulatory access.
This friction were exacerbated by arguments that US consumers were paying a premium for the same drugs than consumers in the Britain and the EU.
In recent months, several large pharmaceutical investments in the UK have been halted or cancelled, while multi-billion-dollar expansions have been announced toward US facilities.
One official stated that the NHS needed to spend more on medicines, noting that its budget allocation on drugs had declined as a proportion of its total funding over the previous ten-year period.
